These inhibitors—imatinib, sunitinib, nilotinib, and dasatanib—were developed for different cancers (chronic myeloid leukemia, gastrointestinal stromal tumors) and different kinases, but they showed activity against KIT. This evidence concerns the gene KIT and gastrointestinal stromal tumor.